Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 12;12:5627–5638. doi: 10.2147/OTT.S198567

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The cytotoxicity of CAR-T cells in combination with DAC pretreatment enhanced lymphoma cell killing in vitro. (A) Lymphoma cells were cultured in the presence of DAC using the indicated concentrations and harvested as targets with or without drug wash-out. CAR-T cells were then added at different E:T ratios and co-cultured for another 24 h. The cytotoxicity of CAR-T cell to lymphoma cells was determined by FACS. (B) CAR-T cell (E) mixed with lymphoma cells (T) treated with or without DAC at E:T ratio 5:1 shows the best efficacy for DAC treatment (*p<0.05, **p<0.01, compared with cells without DAC treatment).

Abbreviations: CAR, chimeric antigen receptor; DAC, decitabine.